BUILD AI
AI development solution for healthcare diagnostics
Company profile
Company profile
Envisionit Deep AI is a UK-based health AI company that addresses critical gaps in medical AI validation and monitoring through its flagship product, RATIFY. The company was founded by Dr. Jaishree Naidoo, a radiologist who recognized that while AI tools performed well in trials, they often behaved unpredictably once deployed in real-world clinical settings. RATIFY is an independent, vendor-agnostic AI assurance platform specifically designed for radiology that provides real-time validation, continuous performance monitoring, drift detection, and human-AI interaction tracking. The platform integrates directly into existing PACS/RIS workflows, operating autonomously in the background without requiring additional clicks from clinicians. By delivering transparent, accountable, and measurable AI performance data, RATIFY helps healthcare providers reduce medico-legal risk from AI misdiagnosis, demonstrate clear ROI on AI investments, eliminate manual quality assurance burdens, and gain insight into bias and model drift. The company's vision is to set the global standard for independent monitoring and assurance of medical AI, ensuring every patient benefits from AI they can trust. Envisionit Deep AI serves hospitals, health systems, and radiology departments seeking to deploy AI tools safely and effectively while maintaining full compliance with EU and FDA standards.
Company description Envisionit DeepAI Ltd official website
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Hybrid · Other deployment with recorded integration context.
Recorded integration context: PACS, RIS.
Company milestones
Featured on Nasdaq (September 2024); Featured on CNN (August 2024); Keynote speaker at ECR 2025 Vienna (March 2025); Partnership with Bayer announced at RSNA 2024; Sifted Summit London speaker (October 2024); Received Transformative Tech grant from Innovate UK; Expanding RATIFY into other medical imaging modalities; Raising capital for global market reach
Partnerships
02 · Flagship portfolio
Selected source-backed Company products and the available commercial context.
AI development solution for healthcare diagnostics
Independent AI assurance platform for radiology delivering real-time validation, monitoring, and drift detection
03 · Research intelligence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
No linked records are currently available.
Clinical validation
No linked records are currently available.
Regulatory
K231871 · 510k · Jan 17, 2024
04 · Company-reported outcomes
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Real-time independent assurance without disrupting workflows
From AI misdiagnosis through continuous monitoring
On AI investments through performance data
Autonomous monitoring replacing manual quality assurance
Collaboration on AI-enabled applications for radiology at RSNA 2024
Partnership advancing healthcare through AI for better outcomes for patients and physicians
05 · Leadership
Leadership profiles and professional links from the current Company record.
06 · Company updates
Recent articles published on Envisionit DeepAI Ltd's official website.
07 · HAIC coverage
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Curated official destinations from the active Company record.
09 · Market pathway
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.